Upgrade to SI Premium - Free Trial

Atossa Therapeutics (ATOS)

4.57 -0.28 (5.77%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26 *Est.)

Latest Headlines

Atossa presents preclinical data on breast cancer drug at ASCO 2026 May 27, 2026 8:30 AM - StreetInsider Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial May 27, 2026 8:30 AM - PR NewsWire Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy May 20, 2026 4:45 PM - PR NewsWire Atos Selected by Viasat to Modernize Global Digital Workplace Operations May 19, 2026 11:09 AM - Globe NewsWire Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Steinhart Richard I May 14, 2026 6:32 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Chen Shu-Chih May 14, 2026 4:28 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Remmel H. Lawrence May 14, 2026 4:26 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Finn Jonathan May 14, 2026 4:26 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Galli Stephen J May 14, 2026 4:25 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Cigler Tessa May 14, 2026 4:25 PM - SEC Filing Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer May 14, 2026 8:30 AM - PR NewsWire Form 8-K ATOSSA THERAPEUTICS, For: May 08 May 8, 2026 8:45 AM - SEC Filing Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update May 8, 2026 8:45 AM - PR NewsWire Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31 May 8, 2026 8:31 AM - SEC Filing Form 8-K ATOSSA THERAPEUTICS, For: May 07 May 8, 2026 8:00 AM - SEC Filing Atossa publishes trial data showing endoxifen reduces breast density May 6, 2026 8:31 AM - StreetInsider Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women May 6, 2026 8:30 AM - PR NewsWire Atos extends CNA partnership with $500 million infrastructure deal May 5, 2026 10:49 AM - StreetInsider Atos secures $500 million multi-year infrastructure deal with CNA May 5, 2026 10:49 AM - StreetInsider Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement May 5, 2026 10:49 AM - Globe NewsWire Atossa gets FDA rare pediatric disease status for McCune-Albright drug May 4, 2026 8:30 AM - StreetInsider Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome May 4, 2026 8:30 AM - PR NewsWire Form 8-K ATOSSA THERAPEUTICS, For: Apr 13 April 16, 2026 8:31 AM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: Mar 27 Filed by: QUAY STEVEN C March 31, 2026 4:57 PM - SEC Filing Form 4 ATOSSA THERAPEUTICS, For: Mar 26 Filed by: Daniel Mark James March 30, 2026 7:23 PM - SEC Filing Form ARS ATOSSA THERAPEUTICS, For: Dec 31 March 30, 2026 5:40 PM - SEC Filing Form DEF 14A ATOSSA THERAPEUTICS, For: Mar 30 March 30, 2026 5:34 PM - SEC Filing Atossa Genetics (ATOS) PT Raised to $25 at H.C. Wainwright March 27, 2026 6:44 AM - StreetInsider Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update March 25, 2026 5:30 PM - PR NewsWire Form 10-K ATOSSA THERAPEUTICS, For: Dec 31 March 25, 2026 5:22 PM - SEC Filing Form 8-K ATOSSA THERAPEUTICS, For: Mar 25 March 25, 2026 5:20 PM - SEC Filing Form PRE 14A ATOSSA THERAPEUTICS, For: Mar 20 March 20, 2026 4:53 PM - SEC Filing The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology March 19, 2026 11:00 AM - StreetInsider Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives March 19, 2026 8:01 AM - PR NewsWire Atossa presents preclinical data on (Z)-endoxifen for muscular dystrophy March 12, 2026 8:03 AM - StreetInsider Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference March 12, 2026 8:01 AM - PR NewsWire Full Article List